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attributable to the study drug. Six patients experienced 
local injection site reactions; three patients reported fatigue 
(grades 1 and 2), and 2 patients experienced myalgia (grade 
1). Six of eight immunologically evaluable patients devel-
oped both cellular and humoral immune responses to vac-
cine. The vaccine also stimulated HLA-A*02, HLA-A*03 
and HLA-A*24 restricted T cell responses. Three patients 
maintained a partial clinical response or stable disease for 
more than 6 months. Median progression-free survival was 
17.6 weeks, and median overall survival was 86.6 weeks 
from study entry with seven of nine patients surviving more 
than 12 months.
Keywords Apoptosis · Glioma · Immunotherapy · 
Peptide · Survivin · Vaccine
Abbreviations
AE  Adverse event
BIRC5  Survivin
CFSE  Carboxyfluorescein succinimidyl ester
CR  Complete response
CTCAE  Common terminology criteria for adverse 
events
CTL  Cytotoxic T lymphocytes
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
GM-CSF  Granulocyte macrophage-colony stimulating 
factor, sargramostim
HBSS  Hank’s balanced salt solution
IAP  Inhibitor of apoptosis protein
KLH  Keyhole limpet hemocyanin
KPS  Karnofsky performance status
OS  Overall survival
PFS  Progression free survival
PR  Partial response
RLT  Regimen-limiting toxicity
Abstract Survivin is an anti-apoptotic protein that is 
highly expressed in many cancers, including malignant 
gliomas. Preclinical studies established that the conju-
gated survivin peptide mimic SurVaxM (SVN53-67/M57-
KLH) could stimulate an anti-tumor immune response 
against murine glioma in vivo, as well as human glioma 
cells ex vivo. The current clinical study was conducted to 
test safety, immunogenicity and clinical effects of the vac-
cine. Recurrent malignant glioma patients whose tumors 
were survivin-positive, and who had either HLA-A*02 
or HLA-A*03 MHC class I allele-positivity, were given 
subcutaneous injections of SurVaxM (500 μg) in Monta-
nide ISA 51 with sargramostim (100 μg) at 2-week inter-
vals. SurVaxM was well tolerated with mostly grade one 
adverse events (AE) and no serious adverse events (SAE) 
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RPCI  Roswell Park Cancer Institute
SAE  Serious adverse event
SD  Stable disease
TCGA  The Cancer Genome Atlas
Introduction
Survivin (BIRC5) is a member of the inhibitor of apoptosis 
protein (IAP) family [1, 2]. Survivin expression in tumors is 
associated with a high rate of disease recurrence and resist-
ance to chemotherapy, and it confers a significant survival 
advantage to tumor cells [3]. Its presence in gliomas and other 
tumors is reportedly associated with a poor prognosis [4]. It is 
expressed in all four subtypes of glioblastoma defined by The 
Cancer Genome Atlas (TCGA) project, including: classical, 
mesenchymal, neural and proneural variants [5].
Although expressed during fetal development [2], sur-
vivin is infrequently detected in the normal tissues of adult 
organisms [6]. Thus, the molecule represents a potential 
target for cancer immunotherapy. One immunohistochemi-
cal study of gliomas demonstrated that 29 of 29 glioma 
specimens (WHO grades II-IV), but not normal brain tis-
sue, contain survivin-positive cells [7]. The mean percent-
age of cells detectable by immunohistochemical methods 
in each specimen was 70.0 % in grade II (low grade) glio-
mas, 81.3 % in grade III (anaplastic) gliomas and 85.0 % in 
grade IV gliomas (glioblastoma). Survivin is also present 
in association with plasma-derived exosomes of glioma 
patients in which its action remains to be defined [8].
As a largely intracellular protein, survivin is degraded by 
the proteasome and resulting epitopes are presented on the 
surface of tumor cells by MHC class I molecules. Accord-
ingly, survivin-specific cytotoxic T lymphocytes (CTL) 
have been identified in some cancer patients [9, 10]. In 
addition to T cell-mediated immunity, many cancer patients 
develop humoral immune responses to survivin with anti-
survivin antibodies detectable in serum [10]. Therefore, 
survivin is potentially immunogenic and such responses 
as these could provide the basis for induction of therapeu-
tic anti-tumor immunity in cancer patients in whom the 
immune system is already primed to recognize survivin.
SurVaxM (SVN53-67/M57-KLH) contains a synthetic 
long peptide mimic that spans amino acids 53 through 67 
of the human survivin protein sequence [11]. The amino 
acid alteration in this peptide (M57) leads to enhanced 
binding of the core survivin epitope to HLA-A*0201 mol-
ecules [11]. The peptide is conjugated to keyhole limpet 
hemocyanin (KLH), which acts as a vaccine adjuvant. The 
long peptide also contains multiple MHC class I epitopes 
that are presentable by other HLA molecules. In addition, 
the long peptide is able to stimulate specific CD4+ cytokine 
support [11, 12]. The presence of MHC class II-restricted 
CD4+ T cells that are specific for tumor-associated anti-
gens has been recognized as an important element for pro-
viding helper factors essential for eliciting and sustaining 
cytotoxic CD8+ responses against tumors [13, 14].
Patients and methods
Study overview
This clinical study (clinicaltrials.gov identifier NCT01250470) 
was conducted in patients with HLA-A*02 and HLA-A*03 
haplotypes who had histologically confirmed survivin-positive 
malignant gliomas that had recurred or progressed following 
standard therapy, including surgery, fractionated radiation ther-
apy and chemotherapy with temozolomide. It was designed to 
test the toxicity (primary outcome) and immunogenicity (sec-
ondary outcome) of SurVaxM in emulsion with Montanide ISA 
51 and given subcutaneously with sargramostim (GM-CSF) as 
a dendritic cell attractant and maturant. This was a nonrand-
omized, single-institution, clinical trial designed to assess a fixed 
dose vaccine regimen. Based on pre-clinical toxicity studies, a 
dose level of 500 μg SurVaxM was selected for testing. A regi-
men of four prime-boost doses at this level was given without 
dose escalation. In order to test the response to extended dos-
ing, patients that survived 6 months without disease progression 
or regimen-limiting toxicity were eligible to receive additional 
booster doses of vaccine. The use of SVN53-67/M57-KLH in 
this study is registered with the USFDA under IND #14674 
held by Roswell Park Cancer Institute (RPCI). The composi-
tion of SVN53-67/M57-KLH (SurVaxM) has been previously 
described [11]. All investigations were performed under a clini-
cal protocol approved by the institutional review board at RPCI 
and in accordance with an assurance filed with and approved by 
the US Department of Health and Human Services. Informed 
consent was obtained from each subject prior to treatment.
Patient eligibility
Inclusion criteria were: age ≥18 years, histologic proof of 
recurrent or progressive glioblastoma, anaplastic astrocy-
toma, anaplastic oligodendroglioma or anaplastic mixed 
glioma following failure of standard therapy, Karnofsky 
performance status (KPS) ≥70, HLA-A*02 or HLA-A*03 
haplotype, survivin expression by tumor cells documented 
by immunohistochemistry, no systemic infection or ongo-
ing antibiotic therapy, white blood cell count ≥3000/
mm3, platelets ≥100,000/mm3, hemoglobin ≥10.0 g/dL, 
AST(SGOT)/ALT(SGPT) <2.5 × ULN, total bilirubin 
≤2.0 mg/dL and serum creatinine ≤1.5× ULN. Patients 
with potential for child-bearing were required to agree to 
the use of acceptable contraceptive methods during treat-
ment and for 3 months after receiving the last dose of 
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vaccine, patients who had had recent cranial surgery were 
eligible for inclusion, but the vaccine could not be adminis-
tered prior to the 14th post-operative day.
Treatment plan
Nine patients were treated with SurVaxM (500 μg) in emul-
sion with Montanide ISA 51 with sargramostim (100 μg) 
every 2 weeks for a total of four doses per patient (prime-
boost phase). All patients in each group were followed for 
at least 6 weeks before the next group of three patients 
could begin treatment to limit the total number of individu-
als exposed to possible toxicity. The dose of vaccine was 
not escalated in an individual patient or between cohorts. 
Patients were followed clinically every 2 weeks for the first 
8 weeks and then monthly until tumor progression or death. 
Patients were assessed for regimen-limiting toxicity (RLT) 
using CTCAEv4.0 criteria (see definition of RLT below). 
Clinical responses were ascertained by neurologic exams 
on schedule and from serial MRI brain scans. Patients who 
survived 6 months without tumor progression, RLT or seri-
ous adverse event (SAE) were eligible to receive additional 
doses of the vaccine every 3 months (booster phase).
Evaluation during study
The primary goal of this study was to assess the safety, 
tolerability and toxicity of the survivin peptide mimic vac-
cine regimen. A secondary goal was to measure immune 
responses to the vaccine, including anti-survivin antibody 
production, survivin-specific multimer immunoreactivity 
and IFNγ mRNA production following vaccination. Ter-
tiary goals were to measure tumor progression after vac-
cination, identify any apparent treatment responses and 
measure survival. Safety was assessed by physical and neu-
rological examinations and laboratory studies.
MRI brain scans were performed serially, and estab-
lished criteria were used to determine radiographic response 
for those with measureable disease. Response categories 
included: (1) complete response (CR), disappearance of all 
enhancing tumor on consecutive MRI scans at least 1 month 
apart, off steroids, and neurologically stable or improved; 
(2) partial response (PR), 50 % reduction in size of enhanc-
ing tumor on consecutive MRI scans at least 1 month apart, 
steroids stable or reduced, and neurologically stable or 
improved; (3) progressive disease (PD), >25 % increase in 
size of enhancing tumor or any new tumor on MRI scans, or 
neurologically worse, and steroids stable or increased; and 
(4) stable disease (SD), all other situations. The measure of 
tumor size is the largest cross-sectional diameter multiplied 
by the largest diameter perpendicular to it. Progression-free 
survival (PFS) is defined as the duration of time from study 
entry to progression on MRI or death.
Clinical evaluability
Patients who received at least one dose of vaccine were 
considered evaluable for the purpose of determining tox-
icity. Patients who received ≥2 doses of vaccine were 
deemed evaluable for immunological response; however, 
those who did not receive ≥2 doses were not replaced 
(patient #4). Patients who received ≥3 doses of vaccine and 
had an MRI scan 8 weeks following initiation of therapy 
were considered evaluable for clinical response. Patients 
who were unevaluable for clinical response were not 
replaced (patient #4).
Safety
NCI common terminology criteria for adverse events 
(CTCAEv4.0) were used to evaluate toxicity. Toxicity was 
considered to be an adverse event possibly, probably or def-
initely related to treatment. The maximum grade of toxicity 
for each category of interest was recorded for each patient, 
and the summary results were tabulated by category and 
grade. Regimen-limiting toxicities (RLT) were defined to 
include: (1) any grade 3 or greater toxicity possibly, prob-
ably or definitely related to the vaccine, (2) any grade 2 or 
greater autoimmune disorder, (3) any grade 2 or greater 
allergic reaction and (4) any peptide vaccine dosing delay 
>2 weeks.
Survival
All patients were followed to ascertain both progression-
free survival (PFS) and median overall survival (OS).
Immunohistochemical studies
Immunohistochemical detection of survivin was performed 
using a Dako Omnis autostainer (Dako North America, Inc. 
Carpinteria, CA) with rabbit monoclonal survivin antibody 
clone EP119 (Bio SB, Santa Barbara, CA). Additional anti-
bodies included: CD4 (4B12, Dako); CD8 (C8/144B, Dako); 
CD20 (L26, Dako); PD-L1/CD274 (SP142, Spring Biosci-
ence). Stained specimens were viewed by the neuropatholo-
gist, co-investigator (JQ), and survivin expression in the 
nucleus and cytoplasm was determined to be present or absent.
Immunologic assessments
Serum antibody measurements
Patient serum was collected and stored at −80 °C. Serial dilu-
tions of clarified serum were applied to unconjugated survivin 
peptide, free KLH and random peptide (20 µg/ml, 1 µg/well) 
on pre-coated ELISA plates (Flat Bottom, Nunc) in triplicate. 
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Samples were incubated at 4 °C overnight and washed (PBS, 
1 % BSA). HRP-conjugated anti-human IgG detection anti-
body (Bio-Rad) was added for 1 h at 25 °C. Plates were 
washed four times, and TMB colorimetric solution (Bioleg-
end) was added at room temperature and developed for 15 min 
and read on a Bio-Rad automated plate reader at 450 nm.
PBMC isolation
Peripheral blood mononuclear cells were isolated within 
3 h from blood samples using Ficoll separation technique. 
Heparinized blood was diluted (1:1) with Hank’s bal-
anced salt solution (HBSS) (Mediatech, Cat#: 21-023-CV). 
Blood/HBSS diluent was layered on top of lymphocyte 
separation medium (LSM; Mediatech, Cat#: 25-072-CV) in 
50-ml conical tubes. Tubes were centrifuged at 400×g for 
30 min. PBMC layer was centrifuged at 600×g for 10 min. 
Cell pellets were re-suspended in 5 ml of CTL wash solu-
tion (Cat#: CTLW010)/RPMI (Mediatech, Cat#: 10-040-
CV) solution. The pooled sample was centrifuged at 500×g 
for 5 min, and the pellet was re-suspended in freezing 
media (10 % DMSO/90 % fetal bovine serum) and trans-
ferred to liquid nitrogen storage.
Multimer analysis
Custom-designed multimers included the following: 
MHC Dextramer-PE (Immudex, Copenhagen, Den-
mark) to A*0201:QMFFCFKEL; A*0301:AQMFFCFK; 
A*0301:DLAQMFFCFK; A*0301:LAQMFFCFK; as well as 
iTag-PE Tetramer (BD Coulter) to A*0201:AQMFFCFKEL; 
and A*24:DLAQMFFCF. Control represents results with a 
nonsense Dextramer (Immudex). Patient PBMC were washed 
in PBS and re-suspended at a concentration of 1 × 106 cells/
ml. 50 µl of sample was added to each well of a round bot-
tom 96 well plate (Costar), and 5 µl of FcR Block reagent was 
incubated with cells at room temperature for 10 min. 10 µl of 
MHC Dextramer or iTag-PE Tetramer was added. The plate 
was vortexed and incubated for 20 min at room tempera-
ture in the dark. Following incubation, 10 µl anti-CD8-FITC 
(500 µg/ml clone T8; BD Coulter) was added, mixed and 
incubated for 30 min at room temperature. Cells were washed 
and re-suspended in PBS-fluorofix buffer (0.5 % paraformal-
dehyde). Data acquisition was obtained using a Fortessa flow 
cytometer running FACSDiva software. Data analysis was 
performed using FCS Express software. Results are based 
upon gating of CD8+ T cells and indicate the percent of cells 
positively labeled with specific tetramer.
T cell proliferation
PBMC were tested for peptide-specific proliferation as 
previously described [15]. PBMC were labeled with car-
boxyfluorescein succinimidyl ester (CFSE) and stimulated 
ex vivo with SVN53-67/M57 or control peptide (100 ng/ml 
over 48 h). Cells were stained for CD4 or CD8 and data 
acquired via FACS analysis and FCS Software as described 
above.
CD4+ and CD8+ separation
SureBeadsTM Protein G Magnetic Beads (Cat. 161-4023, 
Bio-Rad Laboratories, Inc.) were incubated with either 
LEAF CD8a (clone RPA-T8, Cat. 301018, BioLegened) 
or LEAF CD4 (clone OKT4, Cat. 317404, BioLegened). 
The antibody-bound magnetic beads were then incubated 
Table 1  Patient characteristics
a G1, primary glioblastoma; G2, secondary glioblastoma; AG, anaplastic glioma
b Disease burden at first dosing: (–) no measureable contrast enhancement (C.E.); (+), measureable C.E., but <1 cm3; (++), >1 cm3 but ≤5 cm3 
C.E.; (+++), >5 cm3 C.E
c S surgery, R fractionated radiation therapy, SR stereotactic radiosurgery, T temozolomide, B bevacizumab, O other chemotherapy, C carmustine 
wafer implant
d N.E., not evaluable for clinical response due to tumor progression prior to third priming dose of vaccine
Patient HLA-A* Age Sex Tumora Number of recurrences Disease burdenb Prior treatmentsc Priming doses Booster doses
1 01 03 38 M G1 1 + S, R, T, S 4 +
2 01 02 45 F G2 2 +++ S, R, T, S/C, B, SR 4 −
3 02 24 52 F G2 1 + S, R, T, S 4 –
4 01 02 34 M G2 3 +++ S, R, T, SR, S, B, O 2d –
5 02 24 58 M G2 2 + S, R, T, B, SR 4 +
6 02 02 48 F G1 1 ++ S, R, T, S 4 –
7 02 02 57 M AG 2 + S, R, T 4 +
8 01 02 61 M G1 1 + S, R, T, S 4 –
9 02 24 54 M G2 1 + S, T, S, R, T, S, SR 4 –
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with 1 × 105 PBMC. After bead-based CD4/CD8 sepa-
ration, fluorochrome-labeled antibodies to CD8 (clone 
RPA-T8, FITC, Cat. 301050, BioLegend) and CD4 (clone 
OKT4, PE/Cy5, Cat. 317412, BioLegend) were added to 
remaining PBMC. The samples were acquired and ana-
lyzed by FACS as above. Analysis was based upon iso-
lated gating of lymphocyte populations with specific 
CD markers as indicated. Sample purity is based upon 
the percent of specific cells removed from the starting 
population.
Cytokine mRNA isolation and quantification
Patient samples (1 × 105 PBMC) were incubated with 
SVN53-67/M57 peptide at several concentrations (160–
1600 ng/ml) in OpTmizer CTS complete serum-free 
media (Gibco) overnight at 37 °C in 96 well plates. After 
incubation, CD4+ and CD8+ T cells were separated from 
total PBMC by magnetic beads. Anti-human CD4 anti-
body (5 µg; clone OKT4) or anti-human CD8 antibody 
(5 µg; clone RPA-T8) (BioLegend, San Diego, CA) was 
added to Protein G Magnetic SureBeads (BioRad, San 
Diego, CA) and incubated for 60 min at room tempera-
ture with peptide-stimulated cells. Isolated cells were col-
lected and washed in PBS. Total RNA was isolated from 
separated human CD4+ and CD8+ cells using the PureLink 
RNA Mini Kit (Life Technologies) according to manufac-
turer’s instructions. RNA was reverse transcribed using 
Superscript Vilo Master Mix (Life Technologies). cDNA 
concentrations were determined using a Nanodrop 2000 
Spectrophotometer (Thermo Scientific). RT-qPCR was 
performed using a 7900HT Fast Real-Time PCR System 
Fig. 1  Long survivin peptide contained in SVN53-67/M57-KLH is 
shown with brackets indicating empirically confirmed immuno-reac-
tive HLA-A*02, HLA-A*03, HLA-A*11 and HLA-A*24 epitopes 
within it. The position of the cysteine-to-methionine substitution 
(mimic) within the peptide is indicated (dark gray)
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(Life Technologies) with Power SYBR Green PCR Mas-
ter Mix (Life Technologies). Primers for IFNγ had the 
sequences: 5′-GCATCCAAAAGAGTGTGGAG-3′ and 
5′-ATGCTCTTCGACCTCGAAAC-3′. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA was used as 
an internal control, and GAPDH primers had the follow-
ing sequences: 5′-GGTGAAGGTCGGAGTCAACGG-3′ 
and 5′-GAGGTCAATGAAGGGGTCATTG-3′. Reactions 
containing no cDNA were included in each run. Relative 
cytokine mRNA expression levels were calculated by the 
ΔΔCt method using RQ Manager software (Applied Bio-
systems). All samples were run in triplicate. The level of 
GAPDH gene expression served as an endogenous control. 
Data are represented as the ratio of the target gene/GAPDH 
normalized to unstimulated cells. Total mRNA values were 
expressed relative to PBMC RNA. An unpaired t test with 
Welch’s correction was applied to all of the data sets.
Results
Patient characteristics
Patient characteristics are listed in Table 1. All patients 
had previously undergone treatment, including: surgical 
resection, fractionated external beam radiation therapy 
and chemotherapy with temozolomide. Every patient had 
recurrent or progressive disease following failure of stand-
ard therapy at the time of entry. Five of nine patients were 
entered in the trial at first recurrence, and four patients 
were entered after two or more recurrences. Other previ-
ous treatments are listed in Table 1. Eight patients received 
the full complement of four priming doses of vaccine, 
and three patients received at least one booster dose in an 
extended dosing phase as well. One patient was not clini-
cally evaluable due to rapid progression after the second 
dose of vaccine.
Adverse events (AE) and toxicity
All nine patients were evaluable for the purposes of deter-
mining toxicity. SurVaxM demonstrated a good tolerability 
profile with no serious adverse events (SAE) during the 
prime-boost phase of up to four doses. The majority of AEs 
were grade one. Six of nine patients experienced at least 
one injection site reaction (all grade one) with localized 
erythema likely related to the vaccine components. Three 
patients reported fatigue (grades 1 or 2). Two patients expe-
rienced myalgias, probably related to the study regimen. 
Grade 1 lymphopenia was seen in three patients and leu-
kopenia in three patients (grades 1 and 2). The only grade 
3 AE, a seizure, was not related to the vaccine. During the 
extended dosing phase, one patient suffered acute renal 
failure (SAE) due to gabapentin toxicity with complete 
resolution following intravenous hydration. Renal biopsy 
showed no inflammatory tubular changes, immune com-
plex deposition, glomerulonephritis or other evidence of 
immunologic toxicity.
T cell responses
Individual epitopes contained within the long peptide are 
shown in Fig. 1. Survivin-specific T cell responses to vac-
cine were measured using synthetic MHC-peptide com-
plexes (multimers) to CD8+ T cell receptors at baseline 
and after vaccination (Fig. 2a). Patient samples registering 
≥1 % over baseline survivin-specific CD8+ T cells were 
recorded as positive (Fig. 2b). Values that registered ≥0.75 
and <1 % above baseline were recorded as being weakly 
positive. Patients not mounting an immune response 
(<0.75 %) to at least one relevant peptide were recorded as 
being negative. Patients generally developed a measureable 
immune response beginning 8–12 weeks after initial vacci-
nation. Two of three patients in the 3-month booster group 
experienced an increase in multimer-reactive CD8+ T cells 
over a period of 50–150 weeks, suggestive of established 
immune memory. In addition to HLA-A*02 and HLA-
A*03 status, three patients had HLA-A*24 alleles permit-
ting multimer analysis of HLA-A*24-restricted responses 
to vaccine. Two of three such patients had responses to the 
vaccine from both alleles. 
Humoral immune responses
IgG antibodies to epitopes within the survivin peptide 
(Fig. 3a) and to the corresponding wild-type survivin 
Fig. 2  a FACS analysis of representative MHC class I dextramer 
assays of PBMC from a HLA-A*02/24 patient. Multimer binding 
of CD8+ T cells specific for survivin epitopes Pep1 and Pep6 (see 
Fig. 1) is shown. The upper right quadrant of each panel shows sur-
vivin multimer +/CD8+ gated T cells. Week 0 is pre-immunization 
blood sampling. Control represents results with a nonsense dex-
tramer. b Binding of multimers to CD8+ T cell receptors in patients 
measured at weeks 8–150 following study entry. Data acquisition 
was performed by FACS analysis as revealed in a. Patient samples 
registering ≥1 % over baseline survivin-specific CD8+ T cells are 
shown as (filled circle). Patients not mounting an immune response 
to a particular peptide are shown as (open circle). Weakly positive 
patients registering ≥0.75 % and <1 % above baseline are (circled 
times). Custom-designed multimers included: Pep1, HLA-A*0201: 
QMFFCFKEL; Pep2, HLA-A*0201: AQMFFCFKEL; Pep3, 
HLA-A*0301: DLAQMFFCFK; Pep4, HLA-A*0301: LAQMFF-
CFK; Pep5, HLA-A*0301: AQMFFCFK; and Pep6; HLA-A*24: 
DLAQMFFCF. A negative control nonsense multimer was used to 
assess nonspecific binding. MHC Dextramer-PE (Immudex, Copen-
hagen, Denmark) to A*0201:QMFFCFKEL; A*0301:AQMFFCFK; 
A*0301:DLAQMFFCFK; A*0301:LAQMFFCFK; as well as 
iTag-PE Tetramer (BD Coulter) to A*0201:AQMFFCFKEL; and 
A*24:DLAQMFFCF
◂
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peptide (Fig. 3b) were detected in all evaluable patients 
with increasing titer over the course of the vaccination 
series. High titers (>1.0 O.D.) to the survivin vaccine 
peptide were detected in seven of eight patients. Six of 
eight patients developed high titers of antibodies that were 
cross-reactive to the corresponding wild-type survivin 
peptide. In addition, high titers (>1.0 O.D.) to KLH were 
detected in four patients and intermediate titers (>0.75 but 
≤1.0 O.D.) were detected in two patients (data not shown).
Cytokine production in CD4+ and CD8+ cells
CD4+ and CD8+ IFNγ mRNA levels were measured by 
qPCR using cells isolated by magnetic bead separation 
from PBMC obtained at week 12. Depletion of PBMC was 
confirmed to be 94 % (CD4+), and 98 % (CD8+) complete 
by FACS analysis (data not shown). Isolated cells were 
re-stimulated in culture with pooled overlapping survivin 
peptides. Induction of IFNγ mRNA was detected in CD8+ 
cells, but not in CD4+ cells (Fig. 3c). In general, IFNγ 
mRNA levels increased with higher peptide concentrations 
up to a maximum tested concentration of 1.6 µg/ml.
Fig. 3  Antibodies produced in response to vaccination were meas-
ured as a potential biomarker. a IgG antibodies to SVN53-67/M57, 
and b IgG antibodies to SVN53-67 were measured in the serum of 
each patient by ELISA following prime-boost doses, and in those 
patients who entered an extended dosing phase. Seven patients pro-
duced significant levels (>1 O.D.) of SVN53-67/M57 (a) and six 
patients developed high titers (>1 O.D.) of SVN53-67 antibodies 
(b). One patient (#4) was not evaluable due to progression before all 
four prime-boost doses could be administered. c IFNγ mRNA levels 
in isolated CD4+ (left) and CD8+ (right) cells from individual vac-
cinated patients. Cells were stimulated in culture for 2 h with pooled 
overlapping survivin peptides (a.a. 53–67) at the indicated concentra-
tions. qPCR of IFNγ mRNA was performed as described. Relative 
quantitation was performed using the ΔΔCt method, and data were 
standardized to GAPDH mRNA expression and normalized to IFNγ 
mRNA levels in unstimulated cells. CD4+ and CD8+ cell populations 
were verified to be 94 and 98 % pure, respectively, by FACS analysis 
(data not shown)
◂
Fig. 4  FACS analysis of CD8+ 
and CD4+ proliferation in CFSE 
dye-loaded PBMC obtained 
from two patients (patient #1; 
a–d) and (patient #7; e–h) 
12 weeks following vaccination. 
Proliferation was measured in 
response to stimulation of cells 
using either the long (15 amino 
acid) survivin peptide mimic 
(SVN53-67/M57) or a 14 amino 
acid unrelated control peptide 
(seq: LEEKKQNYVVTDHC). 
Cell division is indicated by 
left-shifted peaks
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T cell proliferation
Proliferation of CD4+ and CD8+ cells in response to 
ex vivo stimulation with the survivin peptide vaccine was 
measured by flow cytometry using CFSE-labeled PBMC 
(Fig. 4). Following co-culture with SVN53-67/M57, both 
CD4+ and CD8+ cells were stimulated to proliferate, 
whereas control peptide (irrelevant 14-mer) failed to stimu-
late proliferation.
Tumor lymphocyte infiltrates
Three patients with tumor progression following the vac-
cination regimen underwent biopsy or surgical re-resec-
tion of their tumors with histologic evaluation. In all such 
cases, persistent survivin expression was observed within 
tumor cells (not shown). Tumors also displayed sparse 
focal islands of lymphocytes with co-localization of CD4+, 
CD8+ and CD20+ cells resembling lymph node-like germi-
nal center organization (Fig. 5). In addition, small numbers 
of PD-L1+ cells were observed in these regions.
Radiologic response, tumor progression and survival
One patient with recurrent glioblastoma had a CR and was 
alive and well with no evidence of disease 174 weeks follow-
ing the first dose of vaccine. A second patient had a partial 
radiologic response, but subsequently progressed. Median 
PFS was 17.6 weeks, and median OS was 86.6 weeks in 
this study (Fig. 6). One patient (#5) died of unrelated medi-
cal causes with no tumor progression or mass effect (stable 
disease) documented on MRI scan obtained one week prior 
to death (PFS = OS = 88 weeks). Seven of nine patients sur-
vived more than 52 weeks following study entry.
Fig. 5  Immunohistochemistry 
of T and B cell markers (×200) 
in tissue sections of one patient 
(#8) with recurrent disease 
5.6 months following protocol 
entry. a CD4+ and b CD8+ T 
cells are shown in representative 
fields of the patient’s glioblas-
toma prior to vaccine treatment. 
c CD4+, d CD8+, e CD20+ and 
f PD-L1+ cells within contigu-
ous histologic sections of tumor 
after vaccine treatment and 
subsequent tumor recurrence
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Discussion
The longest surviving patient in this study had a low but 
detectable titer of anti-survivin IgG in pre-immune serum. 
In line with this, previous studies have revealed circulating 
anti-survivin antibodies in patients with colon and lung 
cancer [9, 16] and in glioma patients as well. Similarly, 
T cell reactivity against survivin has been detected in 
cancer patients in the absence of specific vaccination 
[17–19]. Therefore, wild-type survivin is at least weakly 
Fig. 6  Progression-free survival 
(filled triangle) and overall sur-
vival (filled square) of patients. 
Median PFS was 17.6 weeks, 
and median OS was 86.6 weeks 
following study entry. MRI 
showing tumor at diagnosis 
(left), first recurrence (center) 
and 42-month follow-up (right)
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immunogenic and re-stimulation of pre-existing immunity 
may be one aspect of the vaccine’s action.
Clearly, pre-existing anti-survivin immune responses do 
not completely eliminate tumor cells. We have previously 
demonstrated that immunologic tolerance to survivin antigens 
may be broken using molecular mimicry [11, 20]. SurVaxM 
contains a synthetic peptide with an amino acid substitution 
(SVN53-67/M57) that enhances HLA-A*0201 binding act-
ing as a molecular mimic within this contextual background 
[11, 15, 21]. As a result, the core epitope induces a more 
potent immune response in humans than the corresponding 
wild-type survivin peptide [11]. The enhanced binding of 
SVN53-67/M57 to MHC-I molecules enables it to activate T 
cells that can cross-react with the wild-type tumor antigens 
leading to an anti-tumor response [11, 22]. Antigen modifi-
cation may also aid directly in overcoming T cell tolerance 
since patients with non-HLA-A*02 haplotypes (i.e., HLA-
A*03, HLA-A*11 and HLA-A*24) also developed CD8+ T 
cell responses to the vaccine in the current study.
The survivin peptide SVN53-67 contains multiple HLA-
A*02 epitopes, as well as antigen-binding motifs for HLA-
A*03; HLA-A*11, HLA-A*24, HLA-A*26, HLA-A*68, 
HLA-B*13, HLA-B*14, HLA-B*15, HLA-B*35, HLA-
B*39 and HLA-B*44. We have confirmed in this clinical 
study that HLA-A*02, HLA-A*03 and HLA-A*24 patients 
generate survivin-specific humoral and cellular immune 
responses. In pre-clinical studies, we demonstrate that sur-
vivin peptide (SVN53-67/M57) stimulated CTL responses 
against autologous and allogeneic tumor cells from patients 
with HLA-A*2901, HLA-A*3002 haplotypes [11]. More-
over, in one patient treated under a compassionate use 
exemption survivin-specific HLA-A*11-restricted CD8+ 
T cells were generated in high numbers (data not shown). 
Consequently, the peptide vaccine is immunogenic in a rel-
atively large segment of the population.
The survivin gene transcript is processed into a number 
of different mRNA splice variants. All of the various spe-
cies noted to date retain exon 2, which encodes the region 
from which the peptide sequence in SurVaxM is derived. 
In addition to wild-type survivin, the survivin-2B and sur-
vivin–ΔEx3 transcripts, which are translated [23, 24], 
should also be targeted by immune responses generated by 
SurVaxM.
We used anti-survivin and anti-KLH IgG levels as a 
potential biomarker for assessing the immune response to 
vaccine. Eight patients were evaluable (≥2 priming doses) 
for immune response. Seven had high antibody titers to 
the survivin vaccine peptide, and 4 had high titers to KLH. 
Similarly, T cell responses to survivin were seen in seven 
patients following vaccination. Generally, patients with 
minimal disease burden had stronger antibody and T cell 
responses, although there were too few patients to make a 
definitive conclusion about the role of bulk disease in sys-
temic immunosuppression. In addition, CD8+, CD4+ and 
B cell infiltrates were detected in recurrent tumor tissue 
obtained from patients following progression on-study. In 
one patient with a germinal center-like structure, PD-L1 
was also expressed by adjacent glioma cells, suggesting 
that PD-1/PD-L1 interaction in the tumor microenviron-
ment could be important for the immune effector response 
to SurVaxM in some patients [25].
Vaccination strategies utilizing individual CD8+ T cell 
epitopes alone do not routinely produce significant clini-
cal responses. It is critical to stimulate CD4+ helper T cells 
simultaneously to potentiate the CD8+ T cell-driven anti-
tumor response [11, 15, 20, 21, 26]. Specific CD4+ T cell 
stimulation results in the production of IFNγ, IL-2 and IL-4 
which lead to more robust and sustained CTL activity [27, 
28]. The presence of CD4+ support was detected by survivin 
peptide-induced CD4+ proliferation and can be inferred by 
the presence of IgM-to-IgG class switching. Generic pep-
tides, such as tetanus, have been used to boost CD4+ T cell 
activity systemically. However, CD4+ T cells that are gen-
erated through exposure to tumor-associated antigens via 
antigen presentation on MHC class II are tumor-specific and 
play a more direct role in the tumor microenvironment [13, 
14, 26, 27]. SVN53-67/M57-KLH activates multiple sur-
vivin-specific CD8+ T cell clones and stimulates survivin-
specific CD4+ T cell proliferation [11, 12, 15, 21, 29]. Thus, 
in addition to stimulating CD8+ cellular and antibody-medi-
ated immune responses, SurVaxM may provide important 
tumor-specific CD4+ helper support.
This first-in-human study demonstrated the safety, toler-
ability and immunogenicity of SurVaxM in patients with 
recurrent malignant glioma following failure of stand-
ard therapy. Progression-free survival was 17.6 weeks, 
and overall survival was 86.6 weeks. Comparatively, an 
analysis of eight consecutive phase II chemotherapy tri-
als of patients with recurrent malignant glioma, historical 
PFS was 10 weeks and historical OS was 30 weeks [30]. 
Similarly, in a recent phase III clinical trial, which included 
an arm with physician’s choice chemotherapy in patients 
with recurrent glioblastoma, median PFS was 9 weeks and 
median OS was 25.7 weeks in the chemotherapy arm [31]. 
Currently, a larger multi-institutional, phase II clinical trial 
of SurVaxM plus standard therapy (Stupp protocol) is being 
conducted in patients with newly diagnosed glioblastoma.
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